Novartis takes HuCAL-derived bimagrumab into Phase III
This article was originally published in Scrip
Executive Summary
Novartis has begun a pivotal Phase II/III trial in sporadic inclusion body myositis (sIBM) patients with the HuCAL-derived antibody bimagrumab (BYM338). The event triggered an undisclosed milestone payment to MorphoSys, whose HuCAL library was used to identify the antibody. Financial details were not disclosed.